There has been described a ‘window of opportunity’ where superior clinical responses and increased potential for remission are observed when patients with RA are treated early.15 Critically, however, it remains unknown whether Tph cells accumulate in treatment-naïve early RA and contribute to disease establishment, and whether they may present a target for early therapeutic intervention. The gene discussed is TPH1; the disease is rheumatoid arthritis.